Cas:60479-65-4 (2S)-2-(Dibenzylamino)-1-propanol manufacturer & supplier

Chemical Name:(2S)-2-(Dibenzylamino)-1-propanol

CAS.NO:60479-65-4

Synonyms:(S)-2-(N,N-Dibenzylamino)-1-propanol;2-(N,N-dibenzyl)amino-1-propanol;(2S)-2-(Dibenzylamino)-1-propanol;(2S)-2-(dibenzylamino)propan-1-ol;(S)-(+)-2-(Dibenzylamino)-1-propanol;(S)-N,N-dibenzyl-2-amino-1-propanol;S-2-(N,N-dibenzylamino)propanol;(S)-2-(Dibenzylamino)propan-1-ol;N,N-dibenzyl-(S)-2-amino-1-propanol;1-Propanol, 2-[bis(phenylmethyl)amino]-, (2S)-;1-Propanol, 2-(dibenzylamino)-, (S)-;MFCD00191985

Molecular Formula:C₁₇H₂₁NO

Molecular Weight:255.355

HS Code:2922199090

Physical and Chemical Properties:

Melting point:46-48ºC(lit.)

Boiling point:374.2±22.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.583

PSA:23.47000

Exact Mass:255.162308

LogP:4.08

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like (S)-2-(N,N-Dibenzylamino)-1-propanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00191985 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S)-2-(Dibenzylamino)-1-propanol Use and application,S-2-(N,N-dibenzylamino)propanol technical grade,usp/ep/jp grade.

Related News: The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. 2-(4-chloro-2-nitrophenyl)acetic acid manufacturers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. N1,2-Dimethyl-N1-phenyl-1,2-propanediamine suppliers The vaccine has been through the ringer over safety worries before. In April, U.S. authorities halted its use and later tagged it with a warning over reports of rare blood clots occurring alongside bleeding in some recipients. 3,4-dihydroquinoxalin-2-ol vendor & factory Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.,The vaccine has been through the ringer over safety worries before. In April, U.S. authorities halted its use and later tagged it with a warning over reports of rare blood clots occurring alongside bleeding in some recipients.